Gaining access to Brief Admission by self-referral reduced the need for emergency care in adolescents with severe self-harm.
Kyverna surges after IPO, and CEO lays out plans for cell therapy in immune diseases
Kyverna Therapeutics started its first day as a public biotech on a strong note, with its shares $KYTX rising more than 50% Thursday afternoon after